In vivo measurement and biological characterisation of the diabetes-associated mutant insulin p.R46Q (GlnB22-insulin)
| Autor: | Claudia Ulrich Hjørringgaard, Jørgen Olsen, Graeme I. Bell, Julie Støy, Soo-Young Park, Søren Gregersen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Adolescent Endocrinology Diabetes and Metabolism medicine.medical_treatment Blotting Western Amylin 030209 endocrinology & metabolism Maturity onset diabetes of the young Article Cell Line 03 medical and health sciences 0302 clinical medicine Diabetes mellitus Internal medicine Cricetinae Internal Medicine medicine Journal Article Diabetes Mellitus Animals Humans Insulin Insulinoma Proinsulin biology C-Peptide medicine.disease Glucagon Receptor Insulin Islet Amyloid Polypeptide Rats Insulin receptor 030104 developmental biology Endocrinology biology.protein Female Beta cell |
| Zdroj: | Diabetologia Støy, J, Olsen, J, Park, S-Y, Gregersen, S, Hjørringgaard, C U & Bell, G I 2017, ' In vivo measurement and biological characterisation of the diabetes-associated mutant insulin p.R46Q (GlnB22-insulin) ', Diabetologia, vol. 60, no. 8, pp. 1423-1431 . https://doi.org/10.1007/s00125-017-4295-2 |
| ISSN: | 1432-0428 |
| Popis: | AIMS/HYPOTHESIS: Heterozygous mutations in the insulin gene that affect proinsulin biosynthesis and folding are associated with a spectrum of diabetes phenotypes, from permanent neonatal diabetes to MODY. In vivo studies of these mutations may lead to a better understanding of insulin mutation-associated diabetes and point to the best treatment strategy. We studied an 18-year-old woman with MODY heterozygous for the insulin mutation p.R46Q (GlnB22-insulin), measuring the secretion of mutant and wild-type insulin by LC-MS. The clinical study was combined with in vitro studies of the synthesis and secretion of p.R46Q-insulin in rat INS-1 insulinoma cells.METHODS: We performed a standard 75 g OGTT in the 18-year-old woman and measured plasma glucose and serum insulin (wild-type insulin and GlnB22-insulin), C-peptide, proinsulin, glucagon and amylin. The affinity of GlnB22-insulin was tested on human insulin receptors expressed in baby hamster kidney (BHK) cells. We also examined the subcellular localisation, secretion and impact on cellular stress markers of p.R46Q-insulin in INS-1 cells.RESULTS: Plasma GlnB22-insulin concentrations were 1.5 times higher than wild-type insulin at all time points during the OGTT. The insulin-receptor affinity of GlnB22-insulin was 57% of that of wild-type insulin. Expression of p.R46Q-insulin in INS-1 cells was associated with decreased insulin secretion, but not induction of endoplasmic reticulum stress.CONCLUSIONS/INTERPRETATION: The results show that beta cells can process and secrete GlnB22-insulin both in vivo and in vitro. Our combined approach of immunoprecipitation and LC-MS to measure mutant and wild-type insulin may be useful for the study of other mutant insulin proteins. The ability to process and secrete a mutant protein may predict a more benign course of insulin mutation-related diabetes. Diabetes develops when the beta cell is stressed because of increased demand for insulin, as observed in individuals with other insulin mutations that affect the processing of proinsulin to insulin or mutations that reduce the affinity for the insulin receptor. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink